Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | SRC | P12931 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 3/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9227792 | 0.83 | TDP1 (0.53) | TDP1SRCGAAMAPTLMNA | |
| SCHEMBL16843457 | 0.83 | GAA (0.47) | TDP1GAAMAPTLMNAMEN1 | |
| SCHEMBL2862866 | 0.82 | TDP1 (0.51) | TDP1SRCGAAMAPTLMNA | |
| SCHEMBL21844974 | 0.82 | TDP1 (0.51) | TDP1SRCGAAMAPTLMNA | |
| Hydrochloric Acid SCHEMBL20984545 | 0.80 | TDP1 (0.50) | TDP1SRCGAAMAPTLMNA | |
| Bromide SCHEMBL20984474 | 0.80 | TDP1 (0.54) | TDP1SRCGAAMAPTLMNA | |
| SCHEMBL2585556 | 0.79 | KMT2A (0.62) | GAAMAPTLMNAMEN1KMT2A | |
| SCHEMBL21635515 | 0.79 | TDP1 (0.60) | TDP1SRCGAAMAPTLMNA | |
| SCHEMBL3397530 | 0.78 | KMT2A (0.47) | GAAMAPTLMNAMEN1KMT2A | |
| SCHEMBL18469408 | 0.78 | ALDH1A1 (0.52) | TDP1GAAMAPTLMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9475769-B2 | Zinc halide mediated cyclization process leading to tricyclic indoles | GE HEALTHCARE LIMITED (GB) | 2016-10-25 | — | — | US | disclosed |
| US-20150336891-A1 | Zinc Halide Mediated Cyclization Process Leading to Tricyclic Indoles | GE HEALTHCARE LIMITED (GB) | 2015-11-26 | — | — | US | disclosed |
| US-20150335766-A1 | CRYSTALLIZATION PROCESS OF TRICYCLIC INDOLE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2015-11-26 | — | — | US | disclosed |
| WO-2014083163-A1 | ZINC HALIDE MEDIATED CYCLIZATION PROCESS LEADING TO TRICYCLIC INDOLES | GE HEALTHCARE LIMITED (GB) | 2014-06-05 | — | — | WO | disclosed |
| WO-2014083113-A1 | CRYSTALLIZATION PROCESS OF TRICYCLIC INDOLE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2014-06-05 | — | — | WO | disclosed |
| US-20130104887-A1 | Dry Powder Drug Delivery System and Methods | MANNKIND CORPORATION (US) | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150335766-A1 | CRYSTALLIZATION PROCESS OF TRICYCLIC INDOLE DERIVATIVES | IDO1, IDO2, TPH1 | TDP1 1321/4885SRC 538/4885GAA 4260/4885 |
| US-20150336891-A1 | Zinc Halide Mediated Cyclization Process Leading to Tricyclic Indoles | IDO1, IDO2, TPH2 | TDP1 3208/4885SRC 1579/4885GAA 3365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.